Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Selective RET Kinase Inhibition for Patients with RET-Altered Cancers.

Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A.

Ann Oncol. 2018 Apr 18. doi: 10.1093/annonc/mdy137. [Epub ahead of print]

PMID:
29912274
2.

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.

Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, Smith S, Lauriault V, Kolakowski GR, Brandhuber BJ, Larsen PD, Bouhana KS, Winski SL, Hamor R, Wu WI, Parker A, Morales TH, Sullivan FX, DeWolf WE, Wollenberg LA, Gordon PR, Douglas-Lindsay DN, Scaltriti M, Benayed R, Raj S, Hanusch B, Schram AM, Jonsson P, Berger MF, Hechtman JF, Taylor BS, Andrews S, Rothenberg SM, Hyman DM.

Cancer Discov. 2017 Sep;7(9):963-972. doi: 10.1158/2159-8290.CD-17-0507. Epub 2017 Jun 3.

PMID:
28578312
3.

Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response.

Rothenberg SM, Daniels GH, Wirth LJ.

Clin Cancer Res. 2015 Dec 15;21(24):5640-1. doi: 10.1158/1078-0432.CCR-15-2298. No abstract available.

4.

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.

Rothenberg SM, Concannon K, Cullen S, Boulay G, Turke AB, Faber AC, Lockerman EL, Rivera MN, Engelman JA, Maheswaran S, Haber DA.

Elife. 2015 Feb 16;4. doi: 10.7554/eLife.06132.

5.

Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.

Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ.

Clin Cancer Res. 2015 Mar 1;21(5):1028-35. doi: 10.1158/1078-0432.CCR-14-2915. Epub 2014 Dec 30.

6.

Brain tumor cells in circulation are enriched for mesenchymal gene expression.

Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DA.

Cancer Discov. 2014 Nov;4(11):1299-309. doi: 10.1158/2159-8290.CD-14-0471. Epub 2014 Aug 19.

7.

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.

Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA.

Sci Transl Med. 2013 Jul 31;5(196):196ra98. doi: 10.1126/scitranslmed.3005753.

8.

FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma.

Ramsey MR, Wilson C, Ory B, Rothenberg SM, Faquin W, Mills AA, Ellisen LW.

J Clin Invest. 2013 Aug;123(8):3525-38. doi: 10.1172/JCI68899. Epub 2013 Jul 8.

9.

Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.

McBride SM, Rothenberg SM, Faquin WC, Chan AW, Clark JR, Ellisen LW, Wirth LJ.

Head Neck. 2014 Aug;36(8):1181-8. doi: 10.1002/hed.23430. Epub 2014 Mar 10.

10.

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.

Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR.

Clin Cancer Res. 2013 Jun 1;19(11):3088-94. doi: 10.1158/1078-0432.CCR-13-0319. Epub 2013 Apr 3.

11.

Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.

He L, Torres-Lockhart K, Forster N, Ramakrishnan S, Greninger P, Garnett MJ, McDermott U, Rothenberg SM, Benes CH, Ellisen LW.

Cancer Discov. 2013 Mar;3(3):324-37. doi: 10.1158/2159-8290.CD-12-0417. Epub 2012 Dec 28.

12.

The molecular pathogenesis of head and neck squamous cell carcinoma.

Rothenberg SM, Ellisen LW.

J Clin Invest. 2012 Jun;122(6):1951-7. Review.

13.

ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.

Mill CP, Zordan MD, Rothenberg SM, Settleman J, Leary JF, Riese DJ 2nd.

Genes Cancer. 2011 Aug;2(8):792-804. doi: 10.1177/1947601911431080.

14.

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoƫl M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF.

Nat Med. 2011 May;17(5):589-95. doi: 10.1038/nm.2341. Epub 2011 Apr 24.

15.

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.

Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW.

J Clin Invest. 2011 Feb;121(2):809-20. doi: 10.1172/JCI43897. Erratum in: J Clin Invest. 2014 Mar 3;124(3):1418.

16.

Discovering tumor suppressor genes through genome-wide copy number analysis.

Rothenberg SM, Settleman J.

Curr Genomics. 2010 Aug;11(5):297-310. doi: 10.2174/138920210791616734.

17.

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.

Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP Jr, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M.

Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18392-7. doi: 10.1073/pnas.1012539107. Epub 2010 Oct 7.

18.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen EE, Louis DN, Settleman J, Haber DA.

Cancer Res. 2010 Mar 15;70(6):2158-64. doi: 10.1158/0008-5472.CAN-09-3458. Epub 2010 Mar 9.

19.

Modeling oncogene addiction using RNA interference.

Rothenberg SM, Engelman JA, Le S, Riese DJ 2nd, Haber DA, Settleman J.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12480-4. doi: 10.1073/pnas.0803217105. Epub 2008 Aug 18.

20.

Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites.

Diederichs S, Jung S, Rothenberg SM, Smolen GA, Mlody BG, Haber DA.

Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9284-9. doi: 10.1073/pnas.0800803105. Epub 2008 Jun 30.

21.

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.

McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.

Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41. Epub 2007 Dec 6.

22.

Comprehensive mutational analysis of the Moloney murine leukemia virus envelope protein.

Rothenberg SM, Olsen MN, Laurent LC, Crowley RA, Brown PO.

J Virol. 2001 Dec;75(23):11851-62.

Supplemental Content

Loading ...
Support Center